CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 1, 2006--Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, today announced encouraging interim data from its phase 2 clinical study investigating the use of the Company’s lead product candidate, depsipeptide (FK228), in treating patients with metastatic hormone refractory prostate cancer (HRPC). The data were presented at the recent American Society of Clinical Oncology (ASCO) 2006 Prostate Cancer Symposium which took place in San Francisco, CA. The data were presented in a poster presentation that has been awarded a 2006 ASCO Foundation Merit Award.
